Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Sponsor
Second Affiliated Hospital of Soochow University
Study ID
NCT05690191
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Chidamide — DRUG
    Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
  • Lenalidomide — DRUG
    Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
  • Rituximab — DRUG
    Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle

Study Details

A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Key Dates

Start date
Jun 1, 2021
Status verified
Jan 2023
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026

Study Design

Enrollment
169 participants (estimated)

Arms

  • Arm: Chidamide in combination with rituximab and lenalidomide
    Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses); Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle; Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle

Primary Outcome Measure

Objective response rate [ Time Frame: 30 months ]

Related Studies